The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman
S
S
Kaiser Permanente Medical Center, Los Angeles, California.
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D002985:Clinical Protocols; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012074:Remission Induction; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine